Genprex, Inc. Files 2024 Annual Report

Ticker: GNPX · Form: 10-K · Filed: Apr 1, 2025 · CIK: 1595248

Sentiment: neutral

Topics: 10-K, annual-report, financials, pharmaceutical

TL;DR

Genprex 2024 10-K filed: $10.86M assets, $1.49M liabilities. Looks solid.

AI Summary

Genprex, Inc. filed its 10-K for the fiscal year ending December 31, 2024. The company, based in Austin, TX, operates in the Pharmaceutical Preparations sector. Key financial figures for 2024 include total assets of $10.86 million and total liabilities of $1.49 million, resulting in a positive net worth. The filing details their business operations and financial standing for the period.

Why It Matters

This 10-K filing provides investors and stakeholders with a comprehensive overview of Genprex, Inc.'s financial health and operational performance for the fiscal year 2024, including detailed financial statements and risk factors.

Risk Assessment

Risk Level: medium — As a pharmaceutical company, Genprex faces inherent risks related to drug development, regulatory approvals, and market competition, which are detailed within the filing.

Key Numbers

Key Players & Entities

FAQ

What were Genprex, Inc.'s total assets as of December 31, 2024?

Genprex, Inc.'s total assets were $10,860,655 as of December 31, 2024.

What were Genprex, Inc.'s total liabilities as of December 31, 2024?

Genprex, Inc.'s total liabilities were $1,485,902 as of December 31, 2024.

What is Genprex, Inc.'s Standard Industrial Classification code?

Genprex, Inc.'s Standard Industrial Classification code is 2834, for Pharmaceutical Preparations.

Where is Genprex, Inc. headquartered?

Genprex, Inc. is headquartered in Austin, TX.

How much stock-based compensation expense was included for the year ended December 31, 2024?

Stock-based compensation expense included for the year ended December 31, 2024, was $3.3 million.

Filing Details

This Form 10-K (Form 10-K) was filed with the SEC on April 1, 2025 regarding Genprex, Inc. (GNPX).

View full filing on EDGAR

View Full Filing

View this 10-K filing on SEC EDGAR

View on Read The Filing